AB Science specializes in research, development, and sales of kinase protein inhibitors (KPI), therapeutic drugs used in treating cancerous tumors, inflammatory and neuro-degenerative diseases in both humans and animals.

Employees

Sector

Pharmaceuticals

Calendar

30/09 Earnings release - Q2 2026

More about the company

Quotes

Date	Price	Change	Volume
21/26/21	€0.6930	0.00%	4,20,834
20/26/20	€0.6930	-2.26%	4,39,488
19/26/19	€0.7090	-0.42%	7,28,655
18/26/18	€0.7120	-0.97%	1,60,573
17/26/17	€0.7190	-3.36%	4,60,296

Real-time Euronext Paris

More quotes

Quarterly revenue - Rate of surprise

Company calendar

17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT

Market Cap	5.55Cr 6.47Cr 5.19Cr 4.75Cr 8.91Cr 619.36Cr 9.03Cr 61Cr 24Cr 311.13Cr 24Cr 24Cr 1.03TCr	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	5.55Cr 6.47Cr 5.19Cr 4.75Cr 8.91Cr 619.36Cr 9.03Cr 61Cr 24Cr 311.13Cr 24Cr 24Cr 1.03TCr	EV / Sales 2026 *	46.2x	EV / Sales 2027 *	42.7x
Free-Float	95.07%	Yield 2026 *	-	Yield 2027 *	-

17/08	AB Science completes settlement and delivery of its private placement
10/08	AB Science Wraps Up EUR14 Million Private Placements	MT
10/08	AB Science raises €14.2m
13/07	AB Science to Discontinue Three Masitinib-related Clinical Studies	MT
10/07	AB Science streamlines its portfolio and refocuses on two molecules
10/07	AB Science SA Provides Update on Clinical Program, Suspends Non-Priority Clinical Trials and Focuses on Ab8939 and Masitinib Programs	CI
08/07	Stéphane Ledermann takes the helm at AB Science as CEO
07/07	AB Science S.A. Announces Board Changes	CI
07/07	AB Science S.A. Announces CEO Changes	CI
03/07	AB Science S.A. announced that it has received $2.01616 million in funding	CI
01/07	AB Science, successful private placement
01/07	AB Science S.A. announced that it has received ?2.294 million in funding	CI
29/06	AB Science Reports Completion of Step 3 of Phase 1 Evaluating Combination of Ab8939 with Venetoclax for Treatment of Refractory or Relapsed Acute Myeloid Leukemia	CI

17/08	AB Science announces the successful settlement and delivery of securities issued as part of its €14.2 million private placement announced on August 10, 2026	GL
10/08	AB Science announces today the successful completion of capital increases of a total gross amount of EUR 14.2 million	GL
04/08	AB Science : Webconference presentation on masitinib + isoquercetin in COVID-19	PU
10/07	AB Science provides an update on its clinical program, suspending some non-priority clinical trials to focus on two clinical programs	GL
08/07	AB Science : Board of Directors is restructuring its governance to usher in a new phase in the company’s development	PU

17/08	Bourse : Stellantis s'agite, ArgenX communique et PayPal fait monter les enchères
17/08	AB Science procède au règlement-livraison de son placement privé
17/08	AB Science : annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
17/08	AB Science annonce le succès du règlement-livraison des titres émis dans le cadre de son placement privé de 14,2 millions d’euros annoncé le 10 aout 2026
10/08	Au terme d'une séance calme, l'Europe en ordre dispersé

AB Science Share Price

Stocks

AB

FR0010557264

Pharmaceuticals

Valuation: AB Science

Chart: AB Science

Latest news : AB Science

Last Transcript: AB Science

Press Releases: AB Science

News in other languages: AB Science

Quotes and Performance

Course Extremes

Managers and Directors: AB Science

Latest insider transactions

Specialty & Advanced Pharmaceuticals

Financials

Company Profile

Quotes

Quarterly revenue - Rate of surprise

Market Closed - Euronext Paris 09:25:00 21/08/2026 pm IST			After hours 01:29:59 am
0.6930 ^EUR	0.00%		0.6930	0.00%

1 week	-3.75%
Current month	+28.10%
1 month	+22.87%
3 months	-28.26%
6 months	-48.21%
Current year	-54.88%

1 week	0.67	0.74
1 month	0.5	1
Current year	0.5	1.61
1 year	0.5	1.68
3 years	0.5	4.46
5 years	0.5	14.65
10 years	0.5	21.75

Manager	Title	Age	Since
Stéphane Ledermann CEO	Chief Executive Officer	-	07/07/2026
Laurent Guy DFI	Director of Finance/CFO	-	20/11/2009
Christian Fassotte CTO	Chief Tech/Sci/R&D Officer	-	01/04/2018

Director	Title	Age	Since
Alain Moussy CHM	Chairman	-	11/07/2001
Patrick Moussy BRD	Director/Board Member	-	20/09/2011
Cécile de Guillebon BRD	Director/Board Member	64	27/06/2021

Date	Insider	Type	Main position	Quantity	% Market Cap.
09/02/21	Jean-Pierre Kinet	Sell	Founder	14,525	0.0315%
02/02/21	Jean-Pierre Kinet	Sell	Founder	76,104	0.1652%
02/02/21	Jean-Pierre Kinet	Sell	Founder	12,904	0.0280%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AB SCIENCE	0.00%	-3.75%	-46.20%	-76.31%	6.48Cr
MERCK & CO., INC.	+2.30%	+12.46%	+77.47%	+39.33%	37TCr
MERCK KGAA	-0.07%	+1.21%	+24.84%	-12.66%	7.01TCr
HALOZYME THERAPEUTICS, INC.	+1.90%	+9.28%	+50.57%	+152.98%	1.2TCr
KYOWA KIRIN CO., LTD.	-1.85%	-1.38%	-2.77%	+0.39%	865.73Cr
SK BIOPHARMACEUTICALS CO., LTD.	-3.24%	-4.45%	-13.71%	-3.24%	486.21Cr
YUHAN CORPORATION	-1.32%	-0.24%	-27.36%	+17.89%	446.43Cr
BETTA PHARMACEUTICALS CO., LTD.	-8.11%	-25.25%	-22.12%	+13.48%	348.42Cr
SUPERNUS PHARMACEUTICALS, INC.	-3.33%	-4.73%	+6.15%	+46.50%	275.81Cr
SHENYANG XINGQI PHARMACEUTICAL CO.,LTD.	-2.76%	-5.51%	-10.58%	-6.85%	217.18Cr
Average	-1.68%	-2.40%	+3.63%	+17.15%	4.76TCr
Weighted average by Cap.	+1.59%	+7.39%	+64.11%	+32.84%

	2026 *	2027 *
Net sales	12L 14.01L 11.23L 10.28L 19.29L 13Cr 19.54L 1.33Cr 51.73L 6.73Cr 52.6L 51.46L 22Cr	13L 15.18L 12.16L 11.13L 20.9L 15Cr 21.17L 1.44Cr 56.04L 7.29Cr 56.99L 55.75L 24Cr
Net income	-	-
Net Debt	-	-